Bgm (BGM) Non-Current Deffered Revenue (2019 - 2025)
Bgm's (BGM) quarterly Non-Current Deffered Revenue came in at $240154.0 in Q3 2025, up 78.69% year-on-year from $134394.0 in Q3 2024, and up 0.96% on a QoQ basis from $237869.0 in Q1 2025.
Bgm (BGM) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Non-Current Deffered Revenue data on file, last reported at $240154.0 in Q3 2025.
- On a quarterly basis, Non-Current Deffered Revenue rose 78.69% year-over-year to $240154.0 in Q3 2025; TTM through Sep 2025 was $240154.0, a 78.69% increase from a year earlier, with the FY2025 full-year figure at $240154.0, up 78.69% from the prior year.
- Non-Current Deffered Revenue for Q3 2025 stood at $240154.0, up from $237869.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for BGM reached as high as $386.3 billion in Q1 2022 and fell as low as $134394.0 in Q3 2024.
- Historically, Non-Current Deffered Revenue has averaged $72.7 billion across 5 years, with a median of $240154.0 in 2025.
- Across the five-year window, Non-Current Deffered Revenue slumped 100.0% in 2024 and jumped 78.69% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $403745.0 in 2021, then declined by 23.23% to $309943.0 in 2022, then retreated by 28.41% to $221879.0 in 2023, then tumbled by 39.43% to $134394.0 in 2024, then soared by 78.69% to $240154.0 in 2025.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $240154.0 in Q3 2025, $237869.0 in Q1 2025, and $134394.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - | 240,154.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 240,154.00 |
| Mar 31, 2025 | 237,869.00 |
| Sep 30, 2024 | 134,394.00 |
| Mar 31, 2024 | 184,328.00 |
| Sep 30, 2023 | 221,879.00 |
| Mar 31, 2023 | 267.55 Bn |
| Sep 30, 2022 | 309,943.00 |
| Mar 31, 2022 | 386.34 Bn |
| Sep 30, 2021 | 403,745.00 |
| Sep 30, 2020 | 722,137.00 |
| Sep 30, 2019 | 972,338.00 |